Quick Answer
Milestone Pharmaceuticals Inc. reported Operating Income of -$62.14 million for fiscal year 2025.
Milestone Pharmaceuticals Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$62.14M | -47.6% |
| 2024 | -$42.10M | +31.1% |
| 2023 | -$61.10M | -2.4% |
| 2022 | -$59.64M | -38.5% |
| 2021 | -$43.07M | +15.1% |
| 2020 | -$50.71M | +12.4% |
| 2019 | -$57.88M | -143.0% |
| 2018 | -$23.82M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$11.83M | -23.0% | +5.6% |
| June 30, 2025 | -$12.53M | -29.7% | +38.9% |
| March 31, 2025 | -$20.52M | -95.9% | -113.4% |
| September 30, 2024 | -$9.62M | +37.4% | +0.5% |
| June 30, 2024 | -$9.66M | +41.2% | +7.8% |
| March 31, 2024 | -$10.48M | +32.4% | +31.8% |
| September 30, 2023 | -$15.36M | -2.2% | +6.5% |
| June 30, 2023 | -$16.44M | +2.2% | -6.0% |
- Milestone Pharmaceuticals Inc. showed a decrease of -47.6% in Operating Income compared to the prior fiscal year.
- Over the 2018–2025 period, Milestone Pharmaceuticals Inc.’s operating income has declined by 160.9% (from -$23.82 million to -$62.14 million).
- The most recent figure is from Milestone Pharmaceuticals Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 20, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: